COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022
03 mai 2022 08h00 HE
|
COMPASS Pathways
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
03 mai 2022 07h00 HE
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
20 avr. 2022 07h00 HE
|
COMPASS Pathways
London, UK – 20 April 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in Needham Healthcare conference
04 avr. 2022 08h00 HE
|
COMPASS Pathways
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
24 mars 2022 05h00 HE
|
COMPASS Pathways
Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...
COMPASS Pathways to participate in Cowen and Roth investor conferences
02 mars 2022 07h00 HE
|
COMPASS Pathways
LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
24 févr. 2022 07h12 HE
|
COMPASS Pathways
LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and...
COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022
17 févr. 2022 12h21 HE
|
COMPASS Pathways
LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
19 janv. 2022 07h00 HE
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to participate in H.C. Wainwright investor conference
10 janv. 2022 07h00 HE
|
COMPASS Pathways
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...